OncoMatch/Clinical Trials/NCT06014255
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
Is NCT06014255 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Enoblituzumab for prostate cancer.
Treatment: Enoblituzumab — This study evaluates the efficacy, anti-tumor effect, and immunogenicity of neoadjuvant enoblituzumab given before radical prostatectomy. Patients will be randomized to enoblituzumab for a total of 12 weeks beginning 84 days before radical prostatectomy or standard of care arms.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Disease stage
Grade: Gleason sum ≥8 (or 4+3=7 with at least 1 additional high-risk feature such as PSA>20 or cT3) (Gleason)
clinical stage T1c-T3b, N0, M0; Gleason sum of ≥8 (or 4+3=7 with at least 1 additional high-risk feature such as PSA>20 or cT3)
Performance status
ECOG OR KARNOFSKY 0–1
Demographics
Prior therapy
Cannot have received: radiation therapy
Prior radiation therapy for prostate cancer
Cannot have received: hormonal therapy
Prior hormonal therapy for prostate cancer
Cannot have received: biologic therapy
Prior biologic therapy for prostate cancer
Cannot have received: chemotherapy
Prior chemotherapy for prostate cancer
Cannot have received: immunotherapy
Prior immunotherapy/vaccine therapy for prostate cancer
Cannot have received: experimental agent
Prior use of experimental agents for prostate cancer
Lab requirements
Blood counts
wbc >3,000 cells/mm3; anc >1,500 cells/mm3; hemoglobin >9.0 g/dl; platelet count >100,000 cells/mm3
Kidney function
serum creatinine <1.5 × uln
Liver function
serum bilirubin <1.5 × uln; alt <3 × uln; ast <3 × uln; alkaline phosphatase <3 × uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Northewestern University · Chicago, Illinois
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center · Baltimore, Maryland
- University of Minnesota · Minneapolis, Minnesota
- Mayo Clinic · Rochester, Minnesota
- XCancer - Omaha, LLC · Omaha, Nebraska
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06014255 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages